1. Home
  2. KGS vs CELC Comparison

KGS vs CELC Comparison

Compare KGS & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kodiak Gas Services Inc.

KGS

Kodiak Gas Services Inc.

HOLD

Current Price

$75.73

Market Cap

3.5B

Sector

N/A

ML Signal

HOLD

Logo Celcuity Inc.

CELC

Celcuity Inc.

HOLD

Current Price

$123.86

Market Cap

3.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KGS
CELC
Founded
2011
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.5B
3.1B
IPO Year
2023
2017

Fundamental Metrics

Financial Performance
Metric
KGS
CELC
Price
$75.73
$123.86
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
7
9
Target Price
$57.17
$112.56
AVG Volume (30 Days)
1.3M
939.9K
Earning Date
05-06-2026
05-13-2026
Dividend Yield
2.93%
N/A
EPS Growth
58.93
N/A
EPS
0.20
N/A
Revenue
$1,308,100,000.00
N/A
Revenue This Year
$12.30
N/A
Revenue Next Year
$7.96
$720.19
P/E Ratio
$375.50
N/A
Revenue Growth
12.83
N/A
52 Week Low
$30.06
$10.26
52 Week High
$76.68
$151.02

Technical Indicators

Market Signals
Indicator
KGS
CELC
Relative Strength Index (RSI) 79.56 49.39
Support Level $33.33 $100.58
Resistance Level N/A $151.02
Average True Range (ATR) 2.40 8.22
MACD 0.57 -0.89
Stochastic Oscillator 92.24 38.88

Price Performance

Historical Comparison
KGS
CELC

About KGS Kodiak Gas Services Inc.

Kodiak Gas Services Inc is an operator of contract compression infrastructure in the United States. It manages business through two operating segments namely Contract Services and Other Services. Contract Services consists of operating Company-owned and customer-owned compression, and gas treating and cooling infrastructure, pursuant to fixed-revenue contracts to enable the production and gathering of natural gas and oil. Other Services consist of a full range of contract services to support the ancillary needs of customers, including station construction, maintenance and overhaul, freight and crane charges, and other time and material-based offerings.

About CELC Celcuity Inc.

Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.

Share on Social Networks: